A Belfast woman who spent months in hospital after a seizure believes she is alive today thanks to her speedy diagnosis of a ...

A Cleveland Clinic psychiatrist explains how ketamine therapy is transforming depression treatment—and why it works when ...

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...

GRIN Therapeutics & Angelini Pharma ink exclusive collaboration to develop and commercialize radiprodil outside North America: New York Wednesday, May 28, 2025, 15:00 Hrs [IST] GR ...

GRIN Therapeutics Inc. and Angelini Pharma have partnered for the development and commercial rights outside of North America ...

Burden of Memory Disorders and the Role of Traditional MedicineThe growing global population of elderly individuals has led to a dramatic rise in ...

Syndeio Biosciences today announced its launch to pioneer precision neurotherapeutics focused on repairing and enhancing synaptic function in central nervous system (CNS) diseases. The company's ...

Indy biotech Syndeio launches with $90M, led by CEO Derek Small, to develop NMDA receptor drugs for depression & Alzheimer's, ...

Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates ...

Whilst these data suggest the potential for the development of GluN1 antibody therapy, paradoxically GluN1 autoantibodies in humans are associated with the pathogenesis of the autoimmune disease ...